A recent investigation suggests that a drug commonly used to treat liver disease – ursodeoxycholic acid – could slow the progression of Parkinson’s disease.
Browsing: Movement disorders
New research has shed light on the role of C9orf72 within the cells of patients with amyotrophic lateral sclerosis
ISCO develop a parthenogenesis stem cell technology which could potentially avoid the limiting immune-response issues in regenerative medicine.
Neurology Central talks to David Burn, Clinical Director at Parkinson’s UK, to discuss the recently launched Parkinson’s Excellence Network, and the future of Parkinson’s disease treatment and care in the UK.
Available to view on demand: the UC Davis research team present an update on preclinical development of their cell-gene therapy…
This review is a concise summary of nonmotor symptoms in both genetic and idiopathic Parkinson’s disease patients, highlighting the importance of nonmotor symptoms in research and clinical practice of Parkinson’s disease together with some of the potential differences in pathophysiology and clinical features.